Janus Henderson Group PLC Sells 166,849 Shares of argenx SE (NASDAQ:ARGX)

Janus Henderson Group PLC lessened its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 6.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,312,358 shares of the company's stock after selling 166,849 shares during the quarter. argenx comprises 0.7% of Janus Henderson Group PLC's investment portfolio, making the stock its 16th biggest holding. Janus Henderson Group PLC owned about 3.81% of argenx worth $1,422,262,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stephens Inc. AR acquired a new stake in shares of argenx in the 4th quarter worth about $310,000. Ritholtz Wealth Management raised its holdings in shares of argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock worth $552,000 after acquiring an additional 414 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after acquiring an additional 61 shares during the last quarter. Park Avenue Securities LLC raised its holdings in shares of argenx by 40.0% in the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock worth $1,042,000 after acquiring an additional 484 shares during the last quarter. Finally, Atomi Financial Group Inc. acquired a new stake in shares of argenx in the 4th quarter worth about $339,000. Institutional investors own 60.32% of the company's stock.

argenx Stock Performance

argenx stock traded down $10.20 during mid-day trading on Wednesday, reaching $532.27. The company's stock had a trading volume of 486,197 shares, compared to its average volume of 321,553. argenx SE has a 12-month low of $356.38 and a 12-month high of $678.21. The company has a market capitalization of $32.50 billion, a P/E ratio of -604.85 and a beta of 0.57. The firm's fifty day moving average price is $592.11 and its two-hundred day moving average price is $612.79.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $748.34 million. On average, research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ARGX. JMP Securities set a $699.00 target price on shares of argenx in a report on Wednesday. HC Wainwright reiterated a "buy" rating and issued a $720.00 price objective on shares of argenx in a research note on Tuesday, April 8th. Oppenheimer increased their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Wedbush reiterated an "outperform" rating and issued a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Finally, Citigroup reiterated an "outperform" rating on shares of argenx in a research note on Wednesday. Two analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $698.11.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.